Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma

Abstract

Gemcitabine shows marginal antitumor activity in patients with advanced HCC, although the response duration is short-lived. Gemcitabine seems to be particularly promising because of its low toxicity profile. Further studies in combination with other active agents are warranted.

References

Page 1

	Year	Citations
Nonparametric Estimation from Incomplete Observations Edward L. Kaplan, Paul Meier Journal of the American Statistical Association EngineeringAgingLife PredictionRare Event EstimationMortality Rates	1958	38.7K
Reporting results of cancer treatment A. B. Miller, Barth Hoogstraten, M. Staquet, Cancer World Health OrganizationMedicineCancer ManagementClinical EndpointOutcomes Research	1981	7.8K
Optimal two-stage designs for phase II clinical trials Richard Simon Controlled Clinical Trials Clinical Trial ManagementClinical TrialsRandomized Controlled TrialBiostatisticsDrug Trial	1989	3.6K
Cancer: Principles and Practice of Oncology Walter G. Gunn JAMA Preclinical TherapeuticsSimple UniversalSurgical OncologyCancer ManagementCancer Education	1994	1.8K
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. James L. Abbruzzese, Ralf Grunewald, Elizabeth A. Weeks, Journal of Clinical Oncology Molecular PharmacologyOncologyPharmacologyClinical PharmacologyDfdc Dose	1991	757
Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial Ching‐Lung Lai, Anna Suk‐Fong Lok, Pui–Chee Wu, Cancer Surgical OncologyAdria LaboratoriesPathologyPharmacotherapyOncology	1988	361
Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. Prudence A. Francis, James R. Rigas, Mark G. Kris, Journal of Clinical Oncology	1994	218
Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients Yee Chao, Wing‐Kai Chan, MJ Birkhofer, British Journal of Cancer HepatologyPhase IiMedicinePharmacologyPharmacokinetic Study	1998	131
The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer Epie Boven, Hyman M. Schipper, CAM Erkelens, British Journal of Cancer Experimental Human CancerOncologyAnti-tumour EfficacyMedicinePharmacotherapy	1993	108
MDR1 Gene Expression: Its Effect on Drug Resistance to Doxorubicin in Human Hepatocellular Carcinoma Cell Lines J.-G. Park, Seong-Kook Lee, Il Hong, JNCI Journal of the National Cancer Institute	1994	88

Page 1